Develops precision medicine for neurodegenerative diseases, including Alzheimer's and Parkinson's, targeting proteinopathies.
AC Immune SA operates as a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, specializing in the discovery, design, and development of medicines and diagnostic products targeting neurodegenerative diseases associated with protein misfolding. The company's innovative SupraAntigen and Morphomer platforms are engineered to generate vaccines, antibodies, and small molecules that selectively interact with misfolded proteins prevalent in various neurodegenerative disorders.
A cornerstone of AC Immune's pipeline is Crenezumab, a humanized monoclonal antibody designed to target specific conformations implicated in Alzheimer's disease (AD). Currently in Phase II clinical trials for AD prevention, Crenezumab represents a promising advancement in the quest to modify disease progression. Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate in Phase II studies for AD, and ACI-35, an anti-Tau vaccine candidate with completed Phase Ib clinical trials, highlighting the company's multifaceted approach to tackling AD and related neurodegenerative conditions.
Beyond its lead candidates, AC Immune is actively researching small molecule Tau aggregation inhibitors for AD and other NeuroOrphan indications. The company also explores diagnostics targeting proteins like TDP-43, alpha-synuclein, and NLRP3, aiming to enhance early detection and intervention strategies. Supported by strategic collaborations with industry leaders such as Genentech, Biogen, Janssen Pharmaceuticals, Eli Lilly, Life Molecular Imaging, and WuXi Biologics, AC Immune continues to drive innovation in neurodegenerative disease therapeutics, striving to make significant strides in improving patient outcomes world wide.